Solid Tumor
Conditions
Brief summary
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM303 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Interventions
DRUGLM303
Treatment with LM303 injection
Sponsors
Suzhou BlueHorse Therapeutics Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment; 2. The patient has residual lesions that can be used for surgical resection (\>1.5cm3) or biopsy (\>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation; 3. Laboratory inspection index requirements: * Blood routine: lymphocyte ratio \> 20%; neutrophil count \> 1.0 × 10\^9/L; white blood cells \> 3.0 × 10\^9/L; platelets \> 100 × 10\^9/L; hemoglobin \> 80 g/ L; * Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ upper limit of normal x 2.5, if there is liver metastasis ≤ upper limit of normal x 5; alkaline phosphatase (ALP) ≤ upper limit of normal x 2.5; total gallbladder Red pigment (TBIL)≤normal upper limit×1.5; * Renal function: urea ≤ upper limit of normal × 1.5; creatinine (Cr) ≤ upper limit of normal × 1.5; 4. Left ventricular ejection fraction (LVEF) ≥ 50%; 5. ECOG physical condition is 0 or 1; 6. The expected survival time is more than 3 months;
Exclusion criteria
1. Suffering from active or previous autoimmune diseases ; 2. Severe liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and hematopoietic dysfunction; 3. Combined with severe infection or persistent infection and cannot be effectively controlled; 4. Central nervous system metastasis and/or cancerous meningitis; 5. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage; 6. Requires systemic steroid therapy; 7. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb); positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse events (AEs) | Up to 1 years | Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Objective Response | Up to 2 years | Participants displaying objective response associated with the treatment regimen per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. |
| Disease Control Rate (DCR） | Up to 2 years | Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1 |
| Progression-Free Survival (PFS) | Up to 2 years | The time length between TIL infusion and confirmed subsequent disease progression according to RECIST 1.1 |
| The changes of the immunoreactivity during treatment | Up to 2 years | The changes from baseline of systemic immune Response markers: peripheral blood lymphocyte subtypes counts, cytokine, antigen-specific T-lymphocytes |
Countries
China
Contacts
Primary ContactFeng e Li
Outcome results
None listed